Dec. 3 at 4:18 PM
$SLS @Pkinla - i do agree. I think we get up to a
$5B Market Cap on the News --- and it'll continue to climb.
- a T1 Trading Halt - followed by a Gap Up Deep into the Double Digits - ala ABVX
People don't have a clue.
Gps Immunotherapy for AML Maintenance, will set record patient uptake rates: 4x OS advantage, No Toxicity - an infinite Dosing Regime +3 years, zero dropouts, Ez to administer and manufacture, high margin, IP rights into 2037 with Fast Track and Orphan Status . . .
Plus AML CR2/3 is just the Initial Setting.
CR1* is 4x-5x larger - 40-50,000 CR1 patients each year, and there are 1m Diagnosed WT1+ cancers each year...
* Aza+VEN - VIALE-M, a Large Phase 3 Trial Conducted by
$ABBV rhhby for CR1 Maintenance Just Failed - was terminated due to toxicity...
Aza+VEN is BAT for the REGAL Phase 3 CR2 Control Arm Patients --- and its toxic as F...
